metformin has been researched along with nutlin-3a in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apontes, P; Blagosklonny, MV; Demidenko, ZN; Leontieva, OV; Li, F | 1 |
| Hiroshima, K; Morinaga, T; Namiki, T; Sekine, I; Shimada, H; Shimazu, K; Shingyoji, M; Tada, Y; Tagawa, M; Tatsumi, K | 1 |
2 other study(ies) available for metformin and nutlin-3a
| Article | Year |
|---|---|
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cytoprotection; Epithelial Cells; Fibroblasts; G1 Phase; Humans; Imidazoles; Metformin; Nocodazole; Paclitaxel; Piperazines; Sirolimus; Tumor Suppressor Protein p53 | 2011 |
Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Metformin; Piperazines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2017 |